Navigation Links
Halozyme Therapeutics to Present at Upcoming Investor Conferences
Date:9/10/2008

SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will present at two investor conferences in September:

-- Merriman Curhan Ford's 5th Annual Investor Summit to be held at the Mark Hopkins InterContinental Hotel in San Francisco on Monday, September 15, 2008 at 9:30 a.m. Pacific Time (12:30 p.m. Eastern Time); and

-- UBS's 2008 Global Life Sciences Conference to be held at the Grand Hyatt Hotel in New York on Tuesday, September 23, 2008 at 2:30 p.m. Eastern Time (11:30 a.m. Pacific Time).

Interested parties can access a live audio webcast and accompanying slides of the conference presentations via the internet by visiting the Investor Relations section of Halozyme's website at http://www.halozyme.com. Archived presentations will be available on the website for 30 days following the presentation date.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology, and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme also has a number of different enzymes in its portfolio that target significant areas of unmet medical need. For more information visit http://www.halozyme.com.

Halozyme Contact

Robert H. Uhl Senior Director, Investor Relations

(858) 704-8264

ruhl@halozyme.com

Media Contacts

Karen Sparks / Joleen Schultz

Mentus

(858) 455-5500, x275/x215

karen@mentus.com

jschultz@mentus.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
2. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
3. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
4. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
5. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
6. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
9. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
10. Halozyme Therapeutics Amends Stockholder Rights Plan
11. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2017)... 13, 2017  The Alliance for Safe Biologic Medicines ... FDA final guidance on biologic naming: ... in emphasizing the importance of distinct naming for all ... the benefits biosimilars will bring to patients, including new ... the portion of the Guidance dealing with suffix design ...
(Date:1/13/2017)... ... 13, 2017 , ... Two Kalamazoo entrepreneurs have launched AgTonik ... that farms, greenhouses and hydroponics operations use to increase yields and promote plant ... segments of customers using this high grade fulvic acid extracted from a mineral ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... IS A SUCCESS , VTI, Vertebral Technologies, Inc., announces the successful outcome ... expandable device. Since September 2016, VTI (Vertebral Technologies, Inc.) has partnered with ...
(Date:1/12/2017)... ... 2017 , ... Huffman Engineering, Inc. , a leader in control systems ... company’s Lincoln office as a chemical engineer. In his new role, Beck will ... the life science manufacturing and water/wastewater industries. , Prior to joining Huffman Engineering, Beck ...
Breaking Biology Technology:
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, Inc., ... in healthy volunteers of a novel calcium release-activated ... acute pancreatitis. Acute pancreatitis, sudden ... mild disorder, but can be very serious.  In severe ... sepsis, where extended hospital stays, time in the ...
(Date:1/4/2017)... 2017  CES 2017 – Valencell , the ... announced the launch of two new versions of ... biometric sensor modules that incorporate the best of ... expertise. The two new designs include Benchmark BE2.0, ... and Benchmark BW2.0, a 2-LED version of its ...
(Date:12/20/2016)... LONDON , Dec. 20, 2016 ... car sharing, rental and leasing is stoking significant ... of radio frequency technology, Bluetooth low energy (BLE), ... emerge as the next wave of wireless technologies ... vehicle access system to advanced access systems opens ...
Breaking Biology News(10 mins):